Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOXO-260 in RET-Altered Solid Tumors
NCT05241834Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2022
- Primary completion
- Sep 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 1, open-label trial of LOXO-260 in solid tumor, Medullary Thyroid Cancer (MTC), non-small cell lung cancer (NSCLC) and 1 more (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Dose Limiting Toxicity Rate at 28 days. Started Mar 2022; status: completed.
02
Drugs
LOXO-260
03
Conditions
solid tumorMedullary Thyroid Cancer (MTC)non-small cell lung cancer (NSCLC)thyroid neoplasms
Beyond the preview
Go deeper on NCT05241834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05241834.